Key result
Pretreatment with dabigatran etexilate did not increase hematoma volume compared to controls (4.8 vs 3.8 μL; P=0.899), whereas warfarin significantly increased hematoma volume (14.5 μL; P<0.001).
Why the study?
Does dabigatran etexilate prevent hematoma expansion compared to warfarin in experimental intracerebral hemorrhage?
Does dabigatran etexilate prevent hematoma expansion compared to warfarin in experimental intracerebral hemorrhage?
Absolute Event Rate: 4.8% vs 3.8%
p-value: p=0.899
In experimental mouse models of intracerebral hemorrhage, pretreatment with dabigatran etexilate did not increase hematoma volume, whereas warfarin caused significant hematoma expansion, suggesting a potential safety advantage for direct thrombin inhibitors.
No takes yet. Share an insight, caveat, or question.
Dabigatran may confer lower ICH risk than warfarin in this model; leaves open translation to human practice.
Lauer et al. (2011) studied Intracerebral hemorrhage (n=16). Dabigatran etexilate vs. Warfarin and sham-treated controls was evaluated on Hematoma volume 24 hours after collagenase-induced ICH formation (p=0.899). Pretreatment with dabigatran etexilate did not increase hematoma volume compared to controls (4.8 vs 3.8 μL; P=0.899), whereas warfarin significantly increased hematoma volume (14.5 μL; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: